Author Question: The patient is scheduled to begin treatment with amphotericin B. The primary care provider should ... (Read 53 times)

sdfghj · **on:** Jul 23, 2018

The patient is scheduled to begin treatment with amphotericin B. The primary care provider should plan to monitor the patient's:

a. Calcium level
b. Urine output
c. Fluid intake
d. Potassium level

Question 2

Which of the following nucleoside reverse transcriptase inhibitors reduces the risk of perinatal human immunodeficiency virus (HIV) transmission?

a. Didanosine (Videx)
b. Lamivudine (Epivir)
c. Zalcitabine (Hivid)
d. Zidovudine (Retrovir)

bitingbit · **Reply #1 on:** Jul 23, 2018

Answer to Question 1

ANS: B
Nephrotoxicity is the major adverse effect limiting the use of amphotericin B.

Answer to Question 2

ANS: D
To date, the only drugs with a demonstrated ability to reduce the risk of perinatal HIV transmis-sion are zidovudine and nevirapine. Zidovudine is effective in reducing perinatal HIV transmis-sion regardless of maternal viral load.